Drillis Georgios, Goulielmaki Maria, Spandidos Demetrios A, Aggelaki Sofia, Zoumpourlis Vassilios
1st Internal Medicine Clinic, Medical School, Laiko University Hospital of Athens, 115 27 Athens, Greece.
Biomedical Applications Unit, Institute of Chemical Biology, National Hellenic Research Foundation (NHRF), 116 35 Athens, Greece.
Oncol Lett. 2021 May;21(5):393. doi: 10.3892/ol.2021.12654. Epub 2021 Mar 18.
Contemporary developments in molecular biology have been combined with discoveries on the analysis of the role of all non-coding RNAs (ncRNAs) in human diseases, particularly in cancer, by examining their roles in cells. Currently, included among these common types of cancer, are all the lymphomas and lymphoid malignancies, which represent a diverse group of neoplasms and malignant disorders. Initial data suggest that non-coding RNAs, particularly long ncRNAs (lncRNAs), play key roles in oncogenesis and that lncRNA-mediated biology is an important key pathway to cancer progression. Other non-coding RNAs, termed microRNAs (miRNAs or miRs), are very promising cancer molecular biomarkers. They can be detected in tissues, cell lines, biopsy material and all biological fluids, such as blood. With the number of well-characterized cancer-related lncRNAs and miRNAs increasing, the study of the roles of non-coding RNAs in cancer is bringing forth new hypotheses of the biology of cancerous cells. For the first time, to the best of our knowledge, the present review provides an up-to-date summary of the recent literature referring to all diagnosed ncRNAs that mediate the pathogenesis of all types of lymphomas and lymphoid malignancies.
分子生物学的当代发展与对所有非编码RNA（ncRNA）在人类疾病，特别是癌症中的作用分析的发现相结合，通过研究它们在细胞中的作用来实现。目前，在这些常见类型的癌症中，包括所有淋巴瘤和淋巴恶性肿瘤，它们代表了一组多样的肿瘤和恶性疾病。初步数据表明，非编码RNA，特别是长链非编码RNA（lncRNA），在肿瘤发生中起关键作用，并且lncRNA介导的生物学是癌症进展的重要关键途径。其他非编码RNA，称为微小RNA（miRNA或miR），是非常有前景的癌症分子生物标志物。它们可以在组织、细胞系、活检材料和所有生物体液（如血液）中检测到。随着与癌症相关的lncRNA和miRNA的特征明确数量的增加，对非编码RNA在癌症中的作用的研究正在提出关于癌细胞生物学的新假设。据我们所知，本综述首次提供了近期文献的最新总结，这些文献涉及所有已诊断的介导所有类型淋巴瘤和淋巴恶性肿瘤发病机制的ncRNA。
